{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000273","form_type":"8-K","ticker":"PROF","cik":"0001628808","company_name":"Profound Medical Corp.","filed_at":"2026-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.682186+00:00","generated_at":"2026-05-16T10:08:31.617326+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mount Sinai treats first prostate cancer patient with Profound's TULSA-PRO system","bullets":["Mount Sinai Hospital (ranked #6 for Urology) is first in Metro New York to offer TULSA-PRO incision-free, MRI-guided prostate treatment.","Procedure uses AI-powered, directional ultrasound from inside urethra to heat tissue to 55-57°C while protecting nerves; no blood loss or overnight stay.","Patient discharged same day; initial treatment outcome positive.","Profound CEO Arun Menawat noted collaboration between Urology and Interventional Radiology at Mount Sinai."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000273","json":"https://secwatch.observer/filing/0001171843-26-000273.json","markdown":"https://secwatch.observer/filing/0001171843-26-000273.md","text":"https://secwatch.observer/filing/0001171843-26-000273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326000273/0001171843-26-000273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326000273/f8k_011526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:08:31.617326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}